Laurus Labs Limited (LAURUSLABS) - Total Liabilities

Latest as of September 2025: Rs44.82 Billion INR ≈ $484.68 Million USD

Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has total liabilities worth Rs44.82 Billion INR (≈ $484.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Laurus Labs Limited - Total Liabilities Trend (2013–2025)

This chart illustrates how Laurus Labs Limited's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Laurus Labs Limited to evaluate short-term liquidity relative to the company's equity base.

Laurus Labs Limited Competitors by Total Liabilities

The table below lists competitors of Laurus Labs Limited ranked by their total liabilities.

Company Country Total Liabilities
BRENNTAG SE UNSP.ADR/020
F:BNRA
Germany €6.28 Billion
Trade Desk Inc
NASDAQ:TTD
USA $3.67 Billion
BlueFocus Communication Group
SHE:300058
China CN¥19.05 Billion
Evonik Industries AG
F:EVK
Germany €9.81 Billion
Abivax SA
PA:ABVX
France €129.14 Million
FactSet Research Systems Inc
NYSE:FDS
USA $2.09 Billion
Full Truck Alliance Co Ltd ADR
NYSE:YMM
USA $3.62 Billion
Simpson Manufacturing Company Inc
NYSE:SSD
USA $978.37 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Laurus Labs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Laurus Labs Limited (LAURUSLABS) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.32 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.02 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.93 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.48 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Laurus Labs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Laurus Labs Limited (2013–2025)

The table below shows the annual total liabilities of Laurus Labs Limited from 2013 to 2025.

Year Total Liabilities Change
2025-03-31 Rs47.33 Billion
≈ $511.86 Million
+10.81%
2024-03-31 Rs42.71 Billion
≈ $461.94 Million
+18.27%
2023-03-31 Rs36.12 Billion
≈ $390.60 Million
+0.08%
2022-03-31 Rs36.09 Billion
≈ $390.30 Million
+14.57%
2021-03-31 Rs31.50 Billion
≈ $340.66 Million
+59.05%
2020-03-31 Rs19.81 Billion
≈ $214.19 Million
+11.72%
2019-03-31 Rs17.73 Billion
≈ $191.72 Million
+15.56%
2018-03-31 Rs15.34 Billion
≈ $165.91 Million
+15.96%
2017-03-31 Rs13.23 Billion
≈ $143.07 Million
-8.84%
2016-03-31 Rs14.51 Billion
≈ $156.94 Million
+29.36%
2015-03-31 Rs11.22 Billion
≈ $121.32 Million
+22.63%
2014-03-31 Rs9.15 Billion
≈ $98.93 Million
+105.95%
2013-03-31 Rs4.44 Billion
≈ $48.04 Million
--

About Laurus Labs Limited

NSE:LAURUSLABS India Drug Manufacturers - Specialty & Generic
Market Cap
$7.99 Billion
Rs738.96 Billion INR
Market Cap Rank
#2668 Global
#112 in India
Share Price
Rs1368.80
Change (1 day)
-0.07%
52-Week Range
Rs651.00 - Rs1446.80
All Time High
Rs1446.80
About

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more